Search

Search Constraints

You searched for: Author/Creator Moia, Riccardo

Search Results

3. Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. Issue 5 (8th June 2022)

4. Anti‐rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. Issue 2 (27th January 2020)

6. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Issue 5 (24th February 2021)

8. Clonally unrelated Richter syndrome are truly de novo diffuse large B‐cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. (13th July 2022)

9. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases. (28th January 2021)

10. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials. Issue 8 (3rd May 2021)